MetLife Investment Management
ARCT icon

MetLife Investment Management’s Arcturus Therapeutics ARCT Stock Holding History

MetLife Investment Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Buy
15,366
+8,541
+125% +$67.3K ﹤0.01% 2768
2026
Q1 		$52.7K Sell
6,825
-2,532
-27% -$18.5K ﹤0.01% 2676
2025
Q4 		$57.4K Sell
9,357
-6,938
-43% -$74.9K ﹤0.01% 2719
2025
Q3 		$300K Hold
16,295
– – ﹤0.01% 2088
2025
Q2 		$212K Hold
16,295
– – ﹤0.01% 2157
2025
Q1 		$173K Sell
16,295
-381
-2% -$6.05K ﹤0.01% 2276
2024
Q4 		$283K Buy
16,676
+2,955
+22% +$55.6K ﹤0.01% 2114
2024
Q3 		$318K Hold
13,721
– – ﹤0.01% 2031
2024
Q2 		$334K Buy
13,721
+1,394
+11% +$42.3K ﹤0.01% 1943
2024
Q1 		$416K Hold
12,327
– – ﹤0.01% 1781
2023
Q4 		$389K Hold
12,327
– – ﹤0.01% 1835
2023
Q3 		$315K Hold
12,327
– – ﹤0.01% 1914
2023
Q2 		$354K Hold
12,327
– – ﹤0.01% 1921
2023
Q1 		$295K Hold
12,327
– – ﹤0.01% 1969
2022
Q4 		$209K Hold
12,327
– – ﹤0.01% 2222
2022
Q3 		$183K Hold
12,327
– – ﹤0.01% 2355
2022
Q2 		$194K Hold
12,327
– – ﹤0.01% 2342
2022
Q1 		$332K Buy
12,327
+4,915
+66% +$125K ﹤0.01% 2036
2021
Q4 		$274K Hold
7,412
– – ﹤0.01% 1856
2021
Q3 		$354K Sell
7,412
-1,527
-17% -$68.4K ﹤0.01% 1730
2021
Q2 		$302K Hold
8,939
– – ﹤0.01% 1883
2021
Q1 		$369K Hold
8,939
– – ﹤0.01% 1695
2020
Q4 		$388K Buy
8,939
+1,855
+26% +$126K ﹤0.01% 1603
2020
Q3 		$304K Buy
7,084
+1,040
+17% +$51.6K ﹤0.01% 1624
2020
Q2 		$282K Buy
+6,044
New +$208K ﹤0.01% 1688

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

MetLife Investment Management's ARCT Position: Q2 2026 in Review

MetLife Investment Management increased its Arcturus Therapeutics (ARCT) stake by 125% in Q2 2026, buying an estimated $67.3K and bringing the position to 15,366 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #2768.

MetLife Investment Management first reported a position in ARCT in Q2 2020 and has held it in 25 quarters since. The position peaked at $416K in Q1 2024. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • MetLife Investment Management held 15,366 shares of Arcturus Therapeutics worth $103K as of Q2 2026.
  • MetLife Investment Management bought 8,541 Arcturus Therapeutics shares in Q2 2026, an estimated $67.3K.
  • Arcturus Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2768 holding.
  • MetLife Investment Management first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • MetLife Investment Management's Arcturus Therapeutics position peaked at $416K in Q1 2024.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.